Free Trial
NASDAQ:ADIL

Adial Pharmaceuticals (ADIL) Stock Price, News & Analysis

Adial Pharmaceuticals logo
$1.02
+0.01 (+0.99%)
(As of 12:49 PM ET)

About Adial Pharmaceuticals Stock (NASDAQ:ADIL)

Key Stats

Today's Range
$1.00
$1.02
50-Day Range
$0.94
$1.17
52-Week Range
$0.77
$4.17
Volume
22,879 shs
Average Volume
2.78 million shs
Market Capitalization
$6.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Adial Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
14th Percentile Overall Score

ADIL MarketRank™: 

Adial Pharmaceuticals scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Adial Pharmaceuticals are expected to grow in the coming year, from ($1.79) to ($1.51) per share.

  • Price to Book Value per Share Ratio

    Adial Pharmaceuticals has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Adial Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    0.81% of the float of Adial Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Adial Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Adial Pharmaceuticals has recently decreased by 34.19%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Adial Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Adial Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.81% of the float of Adial Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Adial Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Adial Pharmaceuticals has recently decreased by 34.19%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 1 people have searched for ADIL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Adial Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Adial Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.24% of the stock of Adial Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 16.41% of the stock of Adial Pharmaceuticals is held by institutions.

  • Read more about Adial Pharmaceuticals' insider trading history.
Receive ADIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ADIL Stock News Headlines

Blackrock’s Sending THIS Crypto Higher on Purpose
Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin…
Maxim Group Keeps Their Hold Rating on Adial Pharmaceuticals (ADIL)
See More Headlines

ADIL Stock Analysis - Frequently Asked Questions

Adial Pharmaceuticals' stock was trading at $1.86 at the beginning of 2024. Since then, ADIL stock has decreased by 45.2% and is now trading at $1.02.
View the best growth stocks for 2024 here
.

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.39) by $0.20.

Adial Pharmaceuticals shares reverse split on the morning of Monday, August 7th 2023. The 1-25 reverse split was announced on Monday, August 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Adial Pharmaceuticals (ADIL) raised $8 million in an initial public offering (IPO) on Friday, July 27th 2018. The company issued 1,500,000 shares at $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager.

Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adial Pharmaceuticals investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), CrowdStrike (CRWD), CymaBay Therapeutics (CBAY), Arista Networks (ANET) and General Electric (GE).

Company Calendar

Last Earnings
8/13/2024
Today
11/04/2024
Next Earnings (Estimated)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ADIL
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

Net Income
$-5,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.46 per share

Miscellaneous

Free Float
6,070,000
Market Cap
$6.54 million
Optionable
No Data
Beta
1.29
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:ADIL) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners